Patients with multiple sclerosis (MS) who also have food allergies have more relapses than patients with no known food allergy, according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry.
Patients with multiple sclerosis (MS) who also have food allergies have more relapses than patients with no known food allergy, according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry.
A set of 1349 patients completed a self-administered questionnaire on environmental, food, and drug allergies, and they were distributed among 4 allergy groups: environmental (n = 586), food (n = 238), drug (n = 574), and no known allergies (NKA; n = 427).
The researchers then assessed clinical variables—the number of attacks, expanded disability status scale (EDSS), and MS severity score (MSSS)—and radiological variables—presence of gadolinium-enhancing lesions and lesion count—and the association of these variables with the different allergy groups.
"Our findings suggest that MS patients with allergies have more active disease than those without, and that this effect is driven by food allergies," wrote the researchers.
Compared with the NKA group, patients with food allergies had a 1.38 times higher rate for cumulative number of attacks (P = .0062). The food allergy group also showed more than twice the likelihood (P = .0096) of having gadolinium-enhancing lesions on magnetic resonance imaging than the NKA group.
The initial analysis indicated that any allergy was associated with a 22% higher rate of cumulative disease bouts compared with NKA, but that difference disappeared after taking into account potentially influential factors.
“Future prospective studies are needed to confirm our findings and investigate underlying biological mechanisms, which may unveil new therapeutic and preventative strategies for MS,” the authors concluded.
Reference
Fakih R, Diaz-Cruz C, Chua AS, et al. Food allergies are associated with increased disease activity in multiple sclerosis [published online December 18, 2018]. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2018-319301.
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer
October 31st 2024Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.
Read More